Stock comparison
Genmab A/S
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 46D | GMAB |
| Benjamin Graham | 64C | 60D | GMAB |
| Philip Fisher | 48D | 59C | TEVA |
| Peter Lynch | 25F | 53C | TEVA |
| Joel Greenblatt | 76B | 49D | GMAB |
| Charlie Munger | 68C | 50D | GMAB |
| Terry Smith | 71C | 41D | GMAB |
Side-by-side metrics
| Metric | GMAB | TEVA |
|---|---|---|
| Market cap | $16.5B | $39.67B |
| P/E (TTM) | 6.2x | 25.4x |
| EV/EBIT | 12.0x | 24.8x |
| ROIC (TTM) | 43.78% | 11.49% |
| Gross margin | 93.88% | 51.98% |
| Net margin | 18.23% | 9.03% |
| Revenue CAGR 5y | -18.45% | 2.1% |
| EPS CAGR 5y | -23.48% | 34.13% |
| Debt / Equity | 0.1x | 2.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 2.1x+96%
- P/E (TTM)6.2xvs 25.4x+76%
- ROIC (TTM)43.78%vs 11.49%+74%
- EV/EBIT12.0xvs 24.8x+52%
TEVA leads on
- EPS CAGR 5y34.13%vs -23.48%+169%
- Revenue CAGR 5y2.1%vs -18.45%+111%
- Market cap$39.67Bvs $16.5B+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.